<DOC>
	<DOCNO>NCT00003786</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irofulven treat patient metastatic recurrent colorectal cancer .</brief_summary>
	<brief_title>Irofulven Treating Patients With Metastatic Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate patient metastatic locally recurrent adenocarcinoma colon rectum treat 6-hydroxymethylacylfulvene ( MGI-114 ) . II . Determine toxicity treatment regimen patient population . III . Study pharmacokinetics MGI-114 patient . IV . Determine relationship pharmacokinetics MGI-114 clinical outcome include toxicity response therapy patient . OUTLINE : This open label , multicenter study . Patients receive 6-hyroxymethylacylfulvene ( MGI-114 ) IV 5 minute daily 5 day . Courses repeat every 4 week . Treatment continue minimum 2 course absence unacceptable toxic effect disease progression . Patients follow death . PROJECTED ACCRUAL : A total 14-35 patient accrue study within 6-12 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic locally recurrent adenocarcinoma colon rectum Bidimensionally measurable disease Lesions see colonoscopic examination barium study , bone metastasis , CNS lesion , CEA level ascites consider measurable No CNS disease CNS metastases sit measurable disease allow provided appropriate therapy CNS metastasis administer patient neurologically stable require intravenous steroid anticonvulsant therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Zubrod 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 ( platelet transfusion within 7 day ) Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant uncontrolled medical psychiatric illness No serious active infection No active malignancy except nonmelanoma skin cancer carcinoma situ cervix unless adequately treat less 30 % risk relapse PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent prophylactic use growth factor except document febrile neutropenia sepsis Chemotherapy : At least 12 month since prior fluorouracil base adjuvant neoadjuvant chemotherapy No 1 prior regimen No prior chemotherapy advanced metastatic colorectal cancer No concurrent chemotherapy No concurrent investigational antineoplastic drug Endocrine therapy : See Disease Characteristics Radiotherapy : At least 4 week since prior radiotherapy recover No prior radiotherapy site measurable disease No concurrent radiotherapy Surgery : Not specify Other : See Disease Characteristics At least 30 day since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>